Products for Research Use Only

ARQ 621

CAT: 0804-HY-16062-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16062-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ARQ 621 is an allosteric, potent and selective inhibitor of Eg5, a microtubule-based ATPase motor protein involved in cell division. Anti-tumor activity[1]. ARQ 621 is a kinesin inhibitor[2]. ARQ 621 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
CAS Number
1095253-39-6
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335, H400, H410
Target
Kinesin
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/arq-621.html
Purity
99.0
Solubility
DMSO : 110 mg/mL (ultrasonic)
Smiles
O=C(N(CCCN)[C@@H](C(N1NC2=CC=CC=C2)=NC3=C(C=CC(Cl)=C3)C1=O)CC#C)C4=CC=CC(Cl)=C4F
Molecular Formula
C28H24Cl2FN5O2
Molecular Weight
552.43
Precautions
H302, H315, H319, H335, H400, H410
References & Citations
[1]L. C. Chen, et al. First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results from the solid tumors cohort.J Clin Oncol. 2011, May (20) : 3076-3076.|[2]Lindsay S Roberts, et al. Mapping Novel Metabolic Nodes Targeted by Anti-Cancer Drugs that Impair Triple-Negative Breast Cancer Pathogenicity. ACS Chem Biol. 2017 Apr 21;12 (4) :1133-1140.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
Kinesin-5/Eg5/KSP